Member Info for gadgie

https://news.sky.com/story/advanced-cancer-survival-rates-could-double-within-a-decade-say-scientists-12752775

yes and we have AS stating :

This very positive progress reflects the safety profile and tolerability demonstrated in patients enrolled in the study to date.”

medica 22 .... bloody spell check

must admit somewhat surprised no rns regarding medical .... have some tie up now with rapivd

https://www.rapivd.com/news-resources

Thank you GMCC ...

https://www.mondaq.com/pressrelease/100238/carey-olsen-advises-avacta-group-on-55-million-bond-issuance
03 November 2022
Carey Olsen
Carey Olsen has advised Avacta Group PLC (Avacta) on the private placement of £55 million senior unsecured convertible bonds due 2027 to a fund advised by Heights Capital Ireland LLC. Stifel Nicolaus Europe Limited acted as sole private placement agent in respect of the offering.

The bonds were issued by Addition Finance (Jersey) Limited, a wholly owned subsidiary of Avacta incorporated in Jersey. The proceeds of the bond issue were on lent to Avacta. Application will be made to list the bonds on The International Stock Exchange.

A Jersey cash box structure is a well-established financing tool for facilitating access by UK listed companies to immediate funding by way of a convertible bond issue.

The Carey Olsen team was led by partner Simon Marks, with support from senior associate Bryony Bird and associate Catriona Urquhart. The team advised on all aspects of Jersey law and worked alongside onshore counsel Walker Morris and Ashurst. The team will also list the bonds.

Simon said: "We are delighted to have been able to assist Avacta with this deal. Our team has been involved in a significant number of transactions where Jersey issuers have been used by listed companies to issue convertible bonds. This deal uses an interesting variation on the typical structure which allows us to facilitate the investment led by Heights Capital. It was good to see the bond issuance complete and associated acquisition close."

Best post I have read today spot on IMHO ....

apologies if already posted
https://www.imperial.ac.uk/white-city-campus/impact/spotlight/fiona-mclaughlin/
What?is your role at White City?

I am the Chief Scientific Officer for Avacta Therapeutics, headquartered in?Scale Space, White City.? Avacta is a biotechnology company developing a portfolio of clinical and pre-clinical staged assets for the treatment of cancer.? We have two technology platforms, the first is called pre|CISIONTM.? The technology delivers a drug which is much better tolerated, enabling further treament cycles to be administered.

Our second technology is the Affimer® platform, which is a novel biological entity which can be engineered to bind to a vast number of oncology targets, either as a naked Affimer®, or conjugated to a toxic payload.? We are developing Affimer® molecules to a range of tumour microenvironment targets and will advance these into early clinical studies.

https://www.ft.com/content/178c886a-afaf-4806-ab8f-873b9b70c980

Big drugmakers are sitting on almost $300bn fuelling prospects of a buying spree

Wonder how many tests pick up these variants 3rd 4th nov all will be revealed
Overall, data shows significant reductions in neutralisation against several of the newly emergent variants (BA.2.75.2, BA.2.3.20 and BJ.1), compared to BA.2, BA.4 and the dominant BA.5. This suggests that, as immunity begins to wane, these newly emerging BA.2 variants may fuel future waves of SARS-CoV-2 infection.

Dr Meera Chand, Director of Clinical and Emerging Infection at UKHSA,

We do see a list of potential places to play," Merck Chief Executive Robert Davis said on a conference call with analysts. "Obviously, we've got to bring them through to fruition, which we're working to do."

Nov getting very busy
https://www.pegsummiteurope.com/attendee-list

http://events.ebdgroup.com/bioeurope/core/participating-companies2022.php

Avacta attending

Avacta Group Plc (LON:AVCT) is favoured by institutional owners who hold 58% of the company
https://uk.sports.yahoo.com/news/avacta-group-plc-lon-avct-121403533.html

Already posted LFT update last month so ready to go .. reagents selling at 600 plus a pop … what else are they ready to go with … Adeptrix selling sars reagents now and haven’t stopped

GMCC top Drawer …. Thank you

just checking :)
A “CAPTCHA” is a turing test to tell human and bots apart.

Mr Ripley I'm going for new's before end of Q3 .... one thing for sure not long now

Too many opportunities IMHO to bring in either a partner or license deal ... AS has mentioned this several times and as we near Q4 I can't wait !!
41.28 mins in
https://www.youtube.com/watch?v=VwH1OYGgVJM
15.46 min in till end
license deal commercial deal greater shareholder Value plenty of options ... not looking to raise funds
https://www.**********.co.uk/articles/q-a-with-avacta-s-ceo-alastair-smith-cso-fiona-mclaughlin-e49a319/
37 mins in Everything on track ( released 30th Sept ) huge catalyst ....
https://www.**********.co.uk/articles/paul-hill-we-will-see-a-postive-fourth-quarter-plus-some-stocks-to-follow-873c45f

no Einstein's required LOL ....CEO progress Excellent !!!

Attendees ...David Wilson ...Petros Sarantos ...Rachel Mellick ..
https://www.medica-tradefair.com/vis/v1/en/exhibitors/medcom2022.2727408?oid=80396&lang=2&_query=avacta

The Affimer® platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.